Last reviewed · How we verify
NCT02715856
Telemonitoring After Surgery to Preserve Limb Function in Optimizing Mobility in Cancer Survivors With Skeletal Metastases
NA trial testing Monitoring Device in Bone Metastases in 70 participants. Terminated before completion.
28 September 2021
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 70 |
| Start date | 13 April 2016 |
| Primary completion | 28 September 2021 |
| Estimated completion | 28 September 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Monitoring Device
- Physical Activity Measurement
- Quality-of-Life Assessment
- Questionnaire Administration
- Standard Follow-Up Care
- Survey Administration
Conditions studied
- Bone Metastases — all drugs for Bone Metastases →
- Cancer Survivor — all drugs for Cancer Survivor →
- Metastatic Malignant Neoplasm in the Bone — all drugs for Metastatic Malignant Neoplasm in the Bone →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
18 and older, any sex, with Bone Metastases or Cancer Survivor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized pilot trial studies telemonitoring after surgery to preserve limb function in optimizing mobility in cancer survivors with cancer spread to the bone. The use of mobile devices for telemonitoring may improve the delivery of cost-effective, high-quality, standardized surveillance of cancer survivors.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Telemedicine and the assessment of clinician time: a scoping review.
Kidholm K, Jensen LK, Johansson M, Montori VM. · · 2023 · cited 16× · PMID 38099431 · DOI 10.1017/s0266462323002830
Verify or expand the search:
- PubMed search for NCT02715856
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Monitoring Device
Trials testing the same drug.
- NCT03875053 — Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage III-IV Head and Neck Cancer · NA · withdrawn
- NCT03120390 — Physical Activity in Reducing Metabolic Dysregulation (MetD) in Obese Latina Breast Cancer Survivors · NA · withdrawn
- NCT05680961 — Monitoring Movement Disorder Symptoms With a Mobile Medical App on Off-the-shelf Consumer Mobile Devices · unknown
- NCT03574012 — SmART Heart: Study of mHealth Apps to Reduce Cancer-Treatment Effects on the Heart · NA · completed
- NCT03489252 — Remote Activity Monitored by Fitbit Charge 3 in Investigating Daily Step and Sleep Data in Participants With Head and Ne · NA · completed
Other recruiting trials for Bone Metastases
Currently open trials in the same condition.
- NCT06713941 — Management of Bone Metastases · active not recruiting
- NCT06392217 — clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases · recruiting
- NCT06065449 — A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation T · Phase 3 · recruiting
- NCT06487013 — Effectiveness and Safety of ArcBlate Palliative Treatment for Patients With Painful Bone Metastases: A Pivotal Study · NA · recruiting
- NCT06189079 — Arterial Embolization for the Treatment of Bone Metastases: Prospective Observational Study · recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02715856 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 13 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02715856.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing